The DOI matches its Crossref record; 76 of the 76 references it cites were found in a registry or an index.
Targeting the Proprotein Convertase Subtilisin/Kexin Type 9 for the Treatment of Dyslipidemia and Atherosclerosis
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yusuf, S., Hawken, S., Ôunpuu, S., Dans, T., Avezum, A., Lanas, F., McQueen, M., Budaj, A., Pais, P., Varigos, J., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17018-9 · Cited by 12,026
Inflammation in atherosclerosis
Libby, P. (2002) · Nature · doi:10.1038/nature01323 · Cited by 8,315
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
Abifadel, M., Varret, M., Rabès, J.-P., Allard, D., Ouguerram, K., Devillers, M., Cruaud, C., Benjannet, S., Wickham, L., Erlich, D., et al. (2003) · Nature Genetics · doi:10.1038/ng1161 · Cited by 2,985
Diabetes and Atherosclerosis: Epidemiology, Pathophysiology, and Management
Beckman, J. A., Creager, M. A., & Libby, P. (2002) · JAMA · doi:10.1001/jama.287.19.2570 · Cited by 2,724
Receptor-Mediated Endocytosis: Concepts Emerging from the LDL Receptor System
Goldstein, J. L., Brown, M. S., Anderson, R. G. W., Russell, D. W., & Schneider, W. J. (1985) · Annual Review of Cell Biology · doi:10.1146/annurev.cb.01.110185.000245 · Cited by 1,600
Cohen, J., Pertsemlidis, A., Kotowski, I. K., Graham, R., Garcia, C. K., & Hobbs, H. H. (2005) · Nature Genetics · doi:10.1038/ng1509 · Cited by 1,381 · cited 1×
“Conversely, loss-of-function mutations of the PCSK9 gene were discovered and linked to low plasma LDL-C levels and a reduction of cardiovascular risk (7,8).”
BackgroundHorton, J. D., Shah, N. A., Warrington, J. A., Anderson, N. N., Park, S. W., Brown, M. S., & Goldstein, J. L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1534923100 · Cited by 1,270
Seidah, N. G., Benjannet, S., Wickham, L., Marcinkiewicz, J., Jasmin, S. B., Stifani, S., Basak, A., Prat, A., & Chrétien, M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0335507100 · Cited by 1,191
Pearson, T. A., Laurora, I., Chu, H., & Kafonek, S. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.4.459 · Cited by 1,012
Dietschy, J., Turley, S., & Spady, D. (1993) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)35728-x · Cited by 874
The biology and therapeutic targeting of the proprotein convertases
Seidah, N. G., & Prat, A. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3699 · Cited by 759
Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and inlivers of parabiotic mice
Lagace, T. A., Curtis, D. E., Garuti, R., McNutt, M. C., Park, S. W., Prather, H. B., Anderson, N. N., Ho, Y. K., Hammer, R. E., & Horton, J. D. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29383 · Cited by 681 · cited 1×
“In the extracellular pathway, PCSK9 is secreted from the trans-Golgi network and internalized together with the LDLR in clathrin-coated endosomes, promoting degradation of LDLR (18).”
BackgroundEffect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol
Stein, E. A., Mellis, S., Yancopoulos, G. D., Stahl, N., Logan, D., Smith, W. B., Lisbon, E., Gutierrez, M., Webb, C., Wu, R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1105803 · Cited by 664
Frank-Kamenetsky, M., Grefhorst, A., Anderson, N. N., Racie, T. S., Bramlage, B., Akinc, A., Butler, D., Charisse, K., Dorkin, R., Fan, Y., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805434105 · Cited by 642
Zhao, Z., Tuakli-Wosornu, Y., Lagace, T. A., Kinch, L., Grishin, N. V., Horton, J. D., Cohen, J. C., & Hobbs, H. H. (2006) · The American Journal of Human Genetics · doi:10.1086/507488 · Cited by 632
Stein, E. A., Gipe, D., Bergeron, J., Gaudet, D., Weiss, R., Dufour, R., Wu, R., & Pordy, R. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60771-5 · Cited by 588
NARC-1/PCSK9 and Its Natural Mutants
Benjannet, S., Rhainds, D., Essalmani, R., Mayne, J., Wickham, L., Jin, W., Asselin, M.-C., Hamelin, J., Varret, M., Allard, D., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m409699200 · Cited by 587
McKenney, J. M., Koren, M. J., Kereiakes, D. J., Hanotin, C., Ferrand, A.-C., & Stein, E. A. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.03.007 · Cited by 514
Raal, F., Scott, R., Somaratne, R., Bridges, I., Li, G., Wasserman, S. M., & Stein, E. A. (2012) · Circulation · doi:10.1161/circulationaha.112.144055 · Cited by 508
Poirier, S., Mayer, G., Benjannet, S., Bergeron, E., Marcinkiewicz, J., Nassoury, N., Mayer, H., Nimpf, J., Prat, A., & Seidah, N. G. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m708098200 · Cited by 477 · cited 2×
“In addition to the LDLR, PCSK9 interacts with the very low density lipoprotein receptor (VLDLR), which is also expressing the EGF-A domain (35).”
BackgroundAtorvastatin with or without an Antibody to PCSK9 in Primary Hypercholesterolemia
Roth, E. M., McKenney, J. M., Hanotin, C., Asset, G., & Stein, E. A. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1201832 · Cited by 469
Park, S. W., Moon, Y.-A., & Horton, J. D. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m410077200 · Cited by 452
Sullivan, D., Olsson, A. G., Scott, R., Kim, J. B., Xue, A., Gebski, V., Wasserman, S. M., & Stein, E. A. (2012) · JAMA · doi:10.1001/jama.2012.25790 · Cited by 447
Giugliano, R. P., Desai, N. R., Kohli, P., Rogers, W. J., Somaratne, R., Huang, F., Liu, T., Mohanavelu, S., Hoffman, E. B., McDonald, S. T., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61770-x · Cited by 428
Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia
Cunningham, D., Danley, D. E., Geoghegan, K. F., Griffor, M. C., Hawkins, J. L., Subashi, T. A., Varghese, A. H., Ammirati, M. J., Culp, J. S., Hoth, L. R., et al. (2007) · Nature Structural & Molecular Biology · doi:10.1038/nsmb1235 · Cited by 409
Molecular basis for LDL receptor recognition by PCSK9
Kwon, H. J., Lagace, T. A., McNutt, M. C., Horton, J. D., & Deisenhofer, J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0712064105 · Cited by 389
Adipose Tissue and Atherosclerosis: Exploring the Connection
Fantuzzi, G., & Mazzone, T. (2007) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.106.131755 · Cited by 384
Chan, J. C. Y., Piper, D. E., Cao, Q., Liu, D., King, C., Wang, W., Tang, J., Liu, Q., Higbee, J., Xia, Z., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0903849106 · Cited by 371
Koren, M. J., Scott, R., Kim, J. B., Knusel, B., Liu, T., Lei, L., Bolognese, M., & Wasserman, S. M. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61771-1 · Cited by 366
The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population
Hooper, A. J., Marais, A. D., Tanyanyiwa, D. M., & Burnett, J. R. (2007) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2006.08.039 · Cited by 364
Apolipoprotein E Induces Antiinflammatory Phenotype in Macrophages
Baitsch, D., Bock, H. H., Engel, T., Telgmann, R., Müller-Tidow, C., Varga, G., Bot, M., Herz, J., Robenek, H., von Eckardstein, A., et al. (2011) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.111.222745 · Cited by 358
Jeong, H. J., Lee, H.-S., Kim, K.-S., Kim, Y.-K., Yoon, D., & Park, S. W. (2008) · Journal of Lipid Research · doi:10.1194/jlr.m700443-jlr200 · Cited by 331
Maxwell, K. N., Soccio, R. E., Duncan, E. M., Sehayek, E., & Breslow, J. L. (2003) · Journal of Lipid Research · doi:10.1194/jlr.m300203-jlr200 · Cited by 329
The activation and physiological functions of the proprotein convertases
Seidah, N. G., Mayer, G., Zaid, A., Rousselet, E., Nassoury, N., Poirier, S., Essalmani, R., & Prat, A. (2008) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2008.01.030 · Cited by 314 · cited 1×
“The first 8 of these family members (proprotein convertase-1 [PC1], PC2, furin, PC4, PC5, paired basic amino acid cleaving enzyme-4 [PACE4],PC7, and subtilisin kexin isozyme-1) cleave proteinprecursors of growth factors, hormones, receptors, and transmembrane transcription factors passing through the secretory pathway…”
BackgroundAtorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9
Careskey, H. E., Davis, R. A., Alborn, W. E., Troutt, J. S., Cao, G., & Konrad, R. J. (2008) · Journal of Lipid Research · doi:10.1194/jlr.m700437-jlr200 · Cited by 313
Graham, M. J., Lemonidis, K. M., Whipple, C. P., Subramaniam, A., Monia, B. P., Crooke, S. T., & Crooke, R. M. (2007) · Journal of Lipid Research · doi:10.1194/jlr.c600025-jlr200 · Cited by 293
Sueta, C. A., Chowdhury, M., Boccuzzi, S. J., Smith, S. C., Alexander, C. M., Londhe, A., Lulla, A., & Simpson, R. J. (1999) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)00117-4 · Cited by 266
Ferri, N., Tibolla, G., Pirillo, A., Cipollone, F., Mezzetti, A., Pacia, S., Corsini, A., & Catapano, A. L. (2012) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.11.026 · Cited by 258
The crystal structure of PCSK9: A regulator of plasma LDL-cholesterol
Piper, D. E., Jackson, S., Liu, Q., Romanow, W. G., Shetterly, S., Thibault, S. T., Shan, B., & Walker, N. P. C. (2007) · Structure · doi:10.1016/j.str.2007.04.004 · Cited by 251
McNutt, M. C., Lagace, T. A., & Horton, J. D. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.c700095200 · Cited by 251
Roubtsova, A., Munkonda, M. N., Awan, Z., Marcinkiewicz, J., Chamberland, A., Lazure, C., Cianflone, K., Seidah, N. G., & Prat, A. (2011) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.110.220988 · Cited by 244
Adnectins: engineered target-binding protein therapeutics
Lipovsek, D. (2011) · Protein Engineering Design and Selection · doi:10.1093/protein/gzq097 · Cited by 242
Berge, K. E., Ose, L., & Leren, T. P. (2006) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000204337.81286.1c · Cited by 236 · cited 1×
“Accordingly, missense mutations and loss-of function mutations in the PCSK9 gene are associated with increased statin response and hypocholesterolemia, pointing to the potential benefit of PCSK9 inhibition alone and its potentially additive effect in combination with statins (56,57).”
BackgroundEffects of AMG 145 on Low-Density Lipoprotein Cholesterol Levels
Dias, C. S., Shaywitz, A. J., Wasserman, S. M., Smith, B. P., Gao, B., Stolman, D. S., Crispino, C. P., Smirnakis, K. V., Emery, M. G., Colbert, A., et al. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.08.986 · Cited by 235
Inflammation stimulates the expression of PCSK9
Feingold, K. R., Moser, A. H., Shigenaga, J. K., Patzek, S. M., & Grunfeld, C. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.07.023 · Cited by 228
Welder, G., Zineh, I., Pacanowski, M. A., Troutt, J. S., Cao, G., & Konrad, R. J. (2010) · Journal of Lipid Research · doi:10.1194/jlr.m008144 · Cited by 227
Mechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pH
Surdo, P. L., Bottomley, M. J., Calzetta, A., Settembre, E. C., Cirillo, A., Pandit, S., Ni, Y. G., Hubbard, B., Sitlani, A., & Carfí, A. (2011) · The EMBO Reports · doi:10.1038/embor.2011.205 · Cited by 226
Gene Inactivation of Proprotein Convertase Subtilisin/Kexin Type 9 Reduces Atherosclerosis in Mice
Denis, M., Marcinkiewicz, J., Zaid, A., Gauthier, D., Poirier, S., Lazure, C., Seidah, N. G., & Prat, A. (2012) · Circulation · doi:10.1161/circulationaha.111.057406 · Cited by 212
TANG, Z., JIANG, L., PENG, J., REN, Z., WEI, D., WU, C., PAN, L., JIANG, Z., & LIU, L. (2012) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2012.1072 · Cited by 208
Molecular basis of PCSK9 function
Lambert, G., Charlton, F., Rye, K.-A., & Piper, D. E. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.06.010 · Cited by 197
PCSK9‐deficient mice exhibit impaired glucose tolerance and pancreatic islet abnormalities
Mbikay, M., Sirois, F., Mayne, J., Wang, G.-S., Chen, A., Dewpura, T., Prat, A., Seidah, N. G., Chretien, M., & Scott, F. W. (2010) · FEBS Letters · doi:10.1016/j.febslet.2009.12.018 · Cited by 197
Thompson, J. F., Hyde, C. L., Wood, L. S., Paciga, S. A., Hinds, D. A., Cox, D. R., Hovingh, G. K., & Kastelein, J. J. P. (2009) · Circulation: Cardiovascular Genetics · doi:10.1161/circgenetics.108.818062 · Cited by 195
Secreted PCSK9 downregulates low density lipoprotein receptor through receptor-mediated endocytosis
Qian, Y.-W., Schmidt, R. J., Zhang, Y., Chu, S., Lin, A., Wang, H., Wang, X., Beyer, T. P., Bensch, W. R., Li, W., et al. (2007) · Journal of Lipid Research · doi:10.1194/jlr.m700071-jlr200 · Cited by 194
PCSK9 siRNA inhibits HUVEC apoptosis induced by ox-LDL via Bcl/Bax-caspase9-caspase3 pathway
Wu, C.-Y., Tang, Z.-H., Jiang, L., Li, X.-F., Jiang, Z.-S., & Liu, L.-S. (2012) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-011-1028-6 · Cited by 190 · cited 1×
“Knockdown of PCSK9 expression by siRNA significantly reduced ox-LDL-induced apoptosis by altering the Bcl-2/Bax ratio and by inhibiting the activation of both caspase-9 and -3 (39).”
BackgroundPCSK9 binds to multiple receptors and can be functionally inhibited by an EGF-A peptide
Shan, L., Pang, L., Zhang, R., Murgolo, N. J., Lan, H., & Hedrick, J. A. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.07.106 · Cited by 180
The proprotein convertases are potential targets in the treatment of dyslipidemia
Seidah, N. G., & Prat, A. (2007) · Journal of Molecular Medicine · doi:10.1007/s00109-007-0172-7 · Cited by 178
Gupta, N., Fisker, N., Asselin, M.-C., Lindholm, M., Rosenbohm, C., Ørum, H., Elmén, J., Seidah, N. G., & Straarup, E. M. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010682 · Cited by 174
Hampton, E. N., Knuth, M. W., Li, J., Harris, J. L., Lesley, S. A., & Spraggon, G. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0703402104 · Cited by 165
Gitt, A. K., Drexel, H., Feely, J., Ferrières, J., Gonzalez-Juanatey, J. R., Thomsen, K. K., Leiter, L. A., Lundman, P., da Silva, P. M., Pedersen, T., et al. (2012) · European Journal of Preventive Cardiology · doi:10.1177/1741826711400545 · Cited by 162
Le May, C., Kourimate, S., Langhi, C., Chétiveaux, M., Jarry, A., Comera, C., Collet, X., Kuipers, F., Krempf, M., Cariou, B., et al. (2009) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.108.181586 · Cited by 161
Awan, Z. A., Seidah, N. G., MacFadyen, J. G., Benjannet, S., Chasman, D. I., Ridker, P. M., & Genest, J. J. (2011) · Clinical Chemistry · doi:10.1373/clinchem.2011.172932 · Cited by 158
Lindholm, M., Elmén, J., Fisker, N., Hansen, H. F., Persson, R., Møller, M. R., Rosenbohm, C., Ørum, H., Straarup, E. M., & Koch, T. (2011) · Molecular Therapy · doi:10.1038/mt.2011.260 · Cited by 158
Secreted PCSK9 promotes LDL receptor degradation independently of proteolytic activity
Li, J., Tumanut, C., Gavigan, J.-A., Huang, W.-J., Hampton, E. N., Tumanut, R., Suen, K. F., Trauger, J. W., Spraggon, G., Lesley, S. A., et al. (2007) · Biochemical Journal · doi:10.1042/bj20070664 · Cited by 157
Levy, E. H., Ouadda, A. B. D., Spahis, S., Sané, A. T., Garofalo, C., Grenier, É., Emonnot, L., Yara, S., Couture, P., Beaulieu, J., et al. (2013) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.01.023 · Cited by 154
PCSK9 regulates neuronal apoptosis by adjusting ApoER2 levels and signaling
Kysenius, K., Muggalla, P., Mätlik, K., Arumäe, U., & Huttunen, H. J. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-0977-6 · Cited by 137
Sharotri, V., Collier, D. M., Olson, D. R., Zhou, R., & Snyder, P. M. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.363382 · Cited by 108
Rousselet, E., Marcinkiewicz, J., Kriz, J., Zhou, A., Hatten, M. E., Prat, A., & Seidah, N. G. (2011) · Journal of Lipid Research · doi:10.1194/jlr.m014118 · Cited by 107 · cited 2×
“In mice, ischemic stroke led to an upregulation of PCSK9 in the ipsilateral lesion side of the dentate gyrus (40).”
BackgroundLoss- and Gain-of-function PCSK9 Variants
Benjannet, S., Hamelin, J., Chrétien, M., & Seidah, N. G. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.399725 · Cited by 95
Du, F., Hui, Y. Y., Zhang, M., Linton, M. F., Fazio, S., & Fan, D. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.273474 · Cited by 85
Potential of Proprotein Convertase Subtilisin/Kexin Type 9 Based Therapeutics
Stein, E. A., & Swergold, G. D. (2013) · Current Atherosclerosis Reports · doi:10.1007/s11883-013-0310-3 · Cited by 85
PCSK9 Inhibitors: Potential in Cardiovascular Therapeutics
Do, R. Q., Vogel, R. A., & Schwartz, G. G. (2013) · Current Cardiology Reports · doi:10.1007/s11886-012-0345-z · Cited by 43
Genome‐wide expression analysis of cells expressing gain of function mutant D374Y‐PCSK9
Ranheim, T., Mattingsdal, M., Lindvall, J. M., Holla, Ø. L., Berge, K. E., Kulseth, M. A., & Leren, T. P. (2008) · Journal of Cellular Physiology · doi:10.1002/jcp.21519 · Cited by 41
Commentary PCSK9 variants: A new database
Leigh, S. E. A., Leren, T. P., & Humphries, S. E. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.02.006 · Cited by 29
Beyond statins: what to expect from add-on lipid regulating therapy?
Laufs, U., Weintraub, W., & Packard, C. J. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht213 · Cited by 23
Self-citation
Cited by
Macrophage‐mediated cholesterol handling in atherosclerosis
Chistiakov, D. A., Bobryshev, Y. V., & Orekhov, A. N. (2016) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12689 · Cited by 510
Wadhera, R. K., Steen, D. L., Khan, I., Giugliano, R. P., & Foody, J. M. (2016) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2015.11.010 · Cited by 306
Qi, Z., Hu, L., Zhang, J., Yang, W., Liu, X., Jia, D., Yao, Z., Chang, L., Pan, G., Zhong, H., et al. (2021) · Circulation · doi:10.1161/circulationaha.120.046290 · Cited by 268
Colhoun, H. M., Ginsberg, H. N., Robinson, J. G., Leiter, L. A., Müller-Wieland, D., Henry, R. R., Cariou, B., Baccara-Dinet, M. T., Pordy, R., Merlet, L., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw292 · Cited by 172
Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9)
Schulz, R., Schlüter, K.-D., & Laufs, U. (2015) · Basic Research in Cardiology · doi:10.1007/s00395-015-0463-z · Cited by 137
Self-citation
Metadata
- Authors
- Urban, D., Pöss, J., Böhm, M., & Laufs, U.
- Venue
- Journal of the American College of Cardiology
- Publisher
- Elsevier BV
- Published
- 2013-10
- Volume
- 62
- Issue
- 16
- Pages
- 1401-1408
- ISSN
- 0735-1097 (ISSN-L)
- OpenAlex
- W2064328378
- Cited by
- 286
- References
- 76
- FWCI
- 28.74
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.